Aesku PR3 Sensitive and MPO ELISA

  • Antibodies targeting PR3 may be determined by direct ELISA, in which the target antigen is coated directly onto the plastic surface of the microtiterplate, or by capture ELISA. Capture PR3 ELISA tests are coated with anti- PR3 monoclonal antibodies and show a higher sensitivity for PR3 as a better preservation of the epitopes of the small PR3 molecule is observed. However, monoclonal anti-PR3 capture antibodies may also mask epitopes on the PR3 molecule. Therefore, in the Aeskulisa PR3 sensitive test PR3 is coated via small spacer molecules ensuring best accessibility of all relevant epitopes.
  • Kit uses native human PR3 molecule to coat on the microwells for better specificity
  • Uses One Aesku concept ie. Same incubation time, same common reagents like sample buffer, substrate, stop solution and wash buffer, thus user friendly kit and ideal for automation.
  • Breakable microwells & ready to use reagents.
  • FDA cleared & CE – marked product.

Performance Characteristics:

Diagnostic Performance of the AESKULISA MPO and PR3 sensitive tests

AESKULISA PR3 sensitive
50 patients with WG
patients with MPA
Sensitivity 60% 62%
Specificity 100% 100%
PPV 100% 100%
NPV 60% 70%
E. Csemok, D.Ahliquist, S.Ullrich and W, L.Gross. Rheumatology 2002;41:1313 - 1317
WG : Wegener`s grnaulomatosis
MPA: Microscopic polyangiltis
PPV:positive predictive value
NPV : negative predictive value

Diagnostic Sensitivity of anti – PR3 and anti – MPO antibodies

Disease Anti-PR3
Wegener`s granulomatosis 50-95% 10%
Microscopic Polyangitis 45% 45-70%
Churg-Strauss-syndrome 10% 50-60%
Idiopathic glomerulonephritis 25% 65-70%
James B.Peter, Yehuda Shoenfeid(eds), Autoantibodies,Elsever, Amsterdam 1996 Lothar Thomas (ed), Labor und Diagnose, TH+BNooks Veriagosellschaft mbH, FrankfurtMain,1998